Phil Vickers talks new role as head of Longwood’s Solu after Faze shutdown; Regeneron CFO to retire in February

Phil Vickers

Phil Vickers started last week as president and CEO of Solu Therapeutics, a Longwood Fund startup developing small molecule-antibody chimeras.

He takes the place of Longwood executive partner David Donabedian, who has taken the early CEO roles at a…
Click here to view original post